Skip to main content
Original Research, Oral Therapy, Thromboembolism
Evaluation of Direct Oral Anticoagulant Use for Cancer-Associated Thromboembolism
Sarah E. Wheeler, PharmD, Laurie Matt-Amaral, MD, MPH, Chanda Mullen, PhD, Caroline Townley, PharmD, Melanie L. Boros, PharmD, BCPS, BCACP
Sarah E. Wheeler, PharmD; Laurie Matt-Amaral, MD, MPH; Chanda Mullen, PhD; Caroline P. Townley, PharmD, BCOP; Melanie L. Boros, PharmD, BCPS, BCACP
Read More
Case Reports, Dose Escalation/Reduction, Prostate Cancer
Enzalutamide Administration for a Nonhemodialysis Patient with Stage 4 Chronic Kidney Disease and Nonmetastatic Castration-Resistant Prostate Cancer
So Jung Uhm, PharmD, John Malamakal, PharmD, MS, BCPS, BCOP
So Jung Uhm, PharmD; John Malamakal, PharmD, MS, BCPS, BCOP
Read More
Case Reports, Dose Escalation/Reduction, Adverse Events
Dexamethasone-Sparing Strategies Using Netupitant and Palonosetron Fixed-Dose Combination for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: A Case Series
Volkmar Böhme, MD, Ee Min Yeoh, BSc Pharm
Volkmar Böhme, MD; Ee Min Yeoh, BSc Pharm
Read More
HOPA Abstracts
HOPA 2020 Abstracts, Part III
Read More
Ovarian Cancer
ASCO Guidelines Support PARP Inhibitor Use in Maintenance and Recurrent Setting of Advanced Ovarian Cancer
Read More
Ovarian Cancer
Niraparib Efficacy in Advanced Ovarian Cancer Extends to All Biomarker Subgroups
Read More
Ovarian Cancer
Olaparib/Bevacizumab as First-Line Maintenance Reduces Risk for Progression or Death in Patients with Advanced Ovarian Cancer
Read More
Ovarian Cancer
Online Delivery of Genetic Services: No Increase in Cancer Risk Distress versus Telephone Counseling
Read More
Lung Cancer
Rearrangement During Transfection (RET) Fusions and Their Role as Oncogenic Drivers
Read More
Lung Cancer
Molecular Profiling Is Critical for Optimizing NSCLC Therapy
Read More
Page 130 of 199
Results 1291 - 1300 of 1986